Regeneron Pharmaceuticals REGN
$904.35 +$1.45 (+0.16%)
Market closed · Nov 7, 9:50 pm ET · Last extended-hours $900.00 -0.48%
Open$887.22
Prev close$902.90
Day range$887.04 – $911.64
Volume1.12M
Market cap$93.55B
P/E (TTM)20.0
Dividend yield0.41%
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$5.12B+36.3% YoY
Operating profit$2.07B+86.5% YoY
Net profit$1.95B+33.5% YoY
Diluted EPS$18.45+35.5% YoY
Free cash flow$1.43B+3.9% YoY
Operating cash flow$1.78B
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin85.8%
Operating margin30.4%
Net margin28.5%
Return on equity14.9%
Return on assets11.4%
Return on invested capital12.0%
Current ratio3.35
Liabilities / assets24.6%
Cash & investments$9.30B
Total debt$1.99B
Net cash (debt)$7.31B
Free cash flow / sales21.5%
Where the revenue comes from
Quarter 2026/Q2
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $5.12B | $4.29B | $3.61B | $14.34B | $3.88B |
| Total Operating Revenue | $5.12B | $4.29B | $3.61B | $14.34B | $3.88B |
| Cost of Revenue | $573.60M | $576.50M | $669.40M | $2.10B | $584.60M |
| Gross Profit | $4.54B | $3.71B | $2.94B | $12.24B | $3.30B |
| Operating Expense | $2.47B | $2.29B | $2.19B | $8.54B | $2.40B |
| Selling and Admin Expenses | $677.80M | $662.10M | $647.70M | $2.70B | $775.00M |
| Research & Development | $1.79B | $1.63B | $1.54B | $5.85B | $1.63B |
| Operating Profit | $2.07B | $1.42B | $744.80M | $3.70B | $898.60M |
| Net Non-Operating Interest Income (Expense) | $171.20M | $172.30M | $170.60M | $673.00M | $181.10M |
| Non-Operating Interest Income | $181.80M | $183.30M | $183.50M | $716.80M | $193.30M |
| Non-Operating Interest Expense | $10.60M | $11.00M | $12.90M | $43.80M | $12.20M |
| Other Income (Expense) | $43.20M | -$65.00M | -$84.20M | $855.70M | -$36.00M |
| Gain on Sale of Security | $60.30M | $61.90M | $25.00M | $946.10M | -$21.50M |
| Special Income (Charges) | -$21.50M | -$127.00M | -$101.90M | -$124.10M | -$18.70M |
| -Less:Other Special Charges | $21.50M | $127.00M | $101.90M | $124.10M | $18.70M |
| Other Non-Operating Income (Expenses) | $4.40M | $100,000.00 | -$7.30M | $33.70M | $4.20M |
| Pretax Profit | $2.28B | $1.53B | $831.20M | $5.23B | $1.04B |
| Tax | $335.40M | $230.90M | $104.00M | $725.80M | $199.10M |
| Net Profit | $1.95B | $1.30B | $727.20M | $4.50B | $844.60M |
| Profit from Continuing Operations | $1.95B | $1.30B | $727.20M | $4.50B | $844.60M |
| Net Income to Parent Company | $1.95B | $1.30B | $727.20M | $4.50B | $844.60M |
| Net Income to Common Stockholders | $1.95B | $1.30B | $727.20M | $4.50B | $844.60M |
| Basic EPS | $19.16 | $12.62 | $6.99 | $43.07 | $8.21 |
| Diluted EPS | $18.45 | $12.23 | $6.75 | $41.48 | $7.86 |
| Dividend Per Share | $0.94 | $0.94 | $0.94 | $3.52 | $0.88 |
| Other Operating Expenses | – | – | – | -$10.00M | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $44.41B | $41.73B | $40.87B | $40.56B | $40.56B |
| Total Current Assets | $20.80B | $18.45B | $18.21B | $18.02B | $18.02B |
| Cash and Cash Equivalents & Short-Term Investments | $9.30B | $7.99B | $8.75B | $8.61B | $8.61B |
| -Cash and Cash Equivalents | $3.66B | $2.46B | $2.96B | $3.12B | $3.12B |
| -Short Term Investments | $5.64B | $5.54B | $5.79B | $5.49B | $5.49B |
| Receivables | $7.58B | $6.57B | $5.73B | $5.74B | $5.74B |
| -Accounts Receivable | $7.58B | $6.57B | $5.73B | $5.74B | $5.74B |
| Inventory | $1.99B | $3.08B | $3.10B | $3.20B | $3.20B |
| Current Deferred Assets | $900.50M | – | – | – | – |
| Other Current Assets | $1.02B | $801.70M | $620.90M | $474.80M | $474.80M |
| Total Non-Current Assets | $23.61B | $23.28B | $22.66B | $22.54B | $22.54B |
| Net PPE | $5.73B | $5.46B | $5.27B | $5.12B | $5.12B |
| Investments and Advances | $9.56B | $9.83B | $9.79B | $10.26B | $10.26B |
| -Available for Sale Securities | $9.56B | $9.83B | $9.79B | $10.26B | $10.26B |
| Goodwill and Other Intangible Assets | $1.32B | $1.31B | $1.29B | $1.26B | $1.26B |
| Non-Current Deferred Assets | $4.54B | $4.38B | $4.19B | $4.08B | $4.08B |
| Other Non-Current Assets | $2.47B | $2.31B | $2.13B | $1.82B | $1.82B |
| Total Liabilities | $10.91B | $10.02B | $9.45B | $9.30B | $9.30B |
| Total Current Liabilities | $6.20B | $5.53B | $5.11B | $4.37B | $4.37B |
| Payables | $1.14B | $1.16B | $1.03B | $1.29B | $1.29B |
| -Accounts Payable | $1.14B | $1.16B | $1.03B | $939.00M | $939.00M |
| Current Accrued Expenses | $3.59B | $2.97B | $2.72B | $2.53B | $2.53B |
| Short-Term Debt and Capital Lease Obligation | $720.00M | $720.00M | $720.00M | – | – |
| -Current Capital Lease Obligation | $720.00M | $720.00M | $720.00M | – | – |
| Current Deferred Liabilities | $749.80M | $684.80M | $636.20M | $553.00M | $553.00M |
| Total Non-Current Liabilities | $4.70B | $4.49B | $4.34B | $4.93B | $4.93B |
| Long Term Debt and Capital Lease Obligation | $1.99B | $1.99B | $1.99B | $2.71B | $2.71B |
| -Long Term Debt | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B |
| -Long Term Capital Lease Obligation | $0.00 | $0.00 | $0.00 | $720.00M | $720.00M |
| Non-Current Deferred Liabilities | $220.20M | $220.40M | $225.10M | $208.70M | $208.70M |
| Other Non-Current Liabilities | $2.50B | $2.28B | $2.13B | $2.02B | $2.02B |
| Total Equity | $33.50B | $31.71B | $31.42B | $31.26B | $31.26B |
| Stockholders' Equity | $33.50B | $31.71B | $31.42B | $31.26B | $31.26B |
| Capital Stock | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 |
| -Common Stock | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $15.17B | $14.70B | $14.40B | $14.00B | $14.00B |
| Retained Earnings | $39.47B | $37.62B | $36.42B | $35.80B | $35.80B |
| Less: Treasury Stock | $20.95B | $20.57B | $19.41B | $18.61B | $18.61B |
| Gains/Losses Not Affecting Retained Earnings | -$197.50M | -$35.80M | $11.90M | $77.50M | $77.50M |
| -Gross PPE | – | – | – | $7.73B | $7.73B |
| -Accumulated Depreciation | – | – | – | -$2.61B | -$2.61B |
| -Other Intangible Assets | – | – | – | $1.26B | $1.26B |
| -Total Tax Payable | – | – | – | $351.30M | $351.30M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.78B | $813.00M | $1.08B | $4.98B | $1.17B |
| Net cash flow from continuing operations | $1.78B | $813.00M | $1.08B | $4.98B | $1.17B |
| Net Income from Continuing Operations | $1.95B | $1.30B | $727.20M | $4.50B | $844.60M |
| Gain/Loss from Continuing Operations | -$60.30M | -$61.90M | -$25.00M | -$946.10M | $21.50M |
| Depreciation & Depletion & Amortization | $121.00M | $123.70M | $123.20M | $543.70M | $145.00M |
| Deferred Tax | -$182.30M | -$194.40M | -$96.00M | -$785.40M | -$232.50M |
| Other Non-Cash Items | $91.10M | $54.90M | $55.60M | $135.50M | $136.90M |
| Change in Working Capital | -$390.60M | -$649.20M | $36.50M | $532.60M | $5.90M |
| -Change in Receivables | -$1.01B | -$838.50M | $1.20M | $498.10M | -$51.20M |
| -Change in Inventory | $112.30M | -$28.20M | $26.60M | -$275.30M | $2.10M |
| -Change in Prepaid Assets | -$339.00M | -$319.10M | -$198.60M | -$375.30M | $82.80M |
| -Change in Payables and Accrued Expense | $784.50M | $492.70M | $107.70M | $736.80M | -$24.70M |
| -Change In Other Working Capital | $64.80M | $43.90M | $99.60M | -$51.70M | -$3.10M |
| Net cash flow from investing | -$288.10M | -$92.70M | -$428.90M | -$629.10M | $220.30M |
| Net Cash Flow from Continuing Investing Activities | -$288.10M | -$92.70M | -$428.90M | -$629.10M | $220.30M |
| Capital Expenditure | -$300.20M | -$240.20M | -$230.60M | -$898.40M | -$248.70M |
| Net Intangibles Purchase and Sale | -$56.30M | -$51.00M | -$48.90M | -$315.30M | -$42.00M |
| Net Investment Purchase and Sale | $68.40M | $198.50M | -$149.40M | $587.90M | $511.30M |
| Financing Cash Flow | -$290.20M | -$1.22B | -$802.20M | -$3.72B | -$780.10M |
| Net Cash Flow from Continuing Financing Activities | -$290.20M | -$1.22B | -$802.20M | -$3.72B | -$780.10M |
| Net Common Stock Issuance | -$194.50M | -$1.13B | -$704.40M | -$3.33B | -$687.40M |
| Cash Dividends Paid | -$95.70M | -$96.80M | -$97.80M | -$370.30M | -$92.70M |
| Ending Cash Balance | $3.67B | $2.47B | $2.97B | $3.12B | $3.12B |
| Net Change in Cash | $1.21B | -$504.30M | -$152.20M | $634.40M | $610.90M |
| Beginning Cash Balance | $2.47B | $2.97B | $3.12B | $2.49B | $2.51B |
| Effect of Exchange Rate Changes | $500,000.00 | -$300,000.00 | -$900,000.00 | $300,000.00 | -$300,000.00 |
| Free Cash Flow | $1.43B | $521.80M | $799.40M | $3.77B | $880.00M |
| Net PPE Purchase and Sale | – | – | – | $0.00 | $0.00 |
| Net Business Purchase and Sale | – | – | – | -$3.30M | -$300,000.00 |
| Net Other Financing Charges | – | – | – | -$10.30M | $0.00 |
No comments yet — be the first to weigh in on REGN.
Sign in to join the discussion.